Technical Analysis for CRNX - Crinetics Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 15.99 3.36% 0.52
CRNX closed up 3.36 percent on Friday, June 5, 2020, on 78 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical CRNX trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Resistance Bearish 3.36%
Wide Bands Range Expansion 3.36%
Oversold Stochastic Weakness 3.36%
50 DMA Resistance Bearish 0.44%
Wide Bands Range Expansion 0.44%
Oversold Stochastic Weakness 0.44%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.
Cancer Organ Systems Disease Endocrine System Pancreatic Cancer Acromegaly Neuroendocrinology Endocrine Diseases Neuroendocrine Tumors Stage Pharmaceutical

Is CRNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 26.67
52 Week Low 10.63
Average Volume 175,648
200-Day Moving Average 18.61
50-Day Moving Average 16.59
20-Day Moving Average 17.77
10-Day Moving Average 16.51
Average True Range 1.35
ADX 21.27
+DI 14.02
-DI 20.10
Chandelier Exit (Long, 3 ATRs ) 16.64
Chandelier Exit (Short, 3 ATRs ) 19.07
Upper Bollinger Band 20.75
Lower Bollinger Band 14.80
Percent B (%b) 0.2
BandWidth 33.46
MACD Line -0.43
MACD Signal Line -0.06
MACD Histogram -0.371
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.12
Resistance 3 (R3) 17.05 16.61 16.93
Resistance 2 (R2) 16.61 16.32 16.64 16.86
Resistance 1 (R1) 16.30 16.15 16.46 16.37 16.80
Pivot Point 15.86 15.86 15.94 15.89 15.86
Support 1 (S1) 15.55 15.57 15.71 15.62 15.18
Support 2 (S2) 15.11 15.40 15.14 15.12
Support 3 (S3) 14.80 15.11 15.05
Support 4 (S4) 14.87